Inconsistently, glycine-β-muricholic acid, as a selective high-affinity FXR inhibitor, inhibits FXR signaling and improves obesity, insulin resistance, and hepatic steatosis in mouse models of obesity [9]. The gene discussed is NR1H4; the disease is fatty liver disease.